Mitazalimab (ADC-1013) is a monoclonal IgG antibody targeting CD40 and a CD40 agonist with antitumor activity. Mitazalimab activates antigen-presenting cells, induces transient peripheral transcriptome changes, and can be used to study tumors.

Mitazalimab (1 ng/mL-10 μg/mL) was able to activate tumor-associated macrophages (TAM) in human prostate or ovarian cancer samples. [2]

Mitazalimab (100 μg/mouse, intraperitoneal injection, single dose) was able to activate splenic dendritic cells and B-cells in naïve hCD40tg mice and induced OVA-specific CD8+ T-cell expansion under OVA reprocessing conditions (200 μg intravenously, 3 times over 7 consecutive days). In addition, Mitazalimab (100 and 300 μg/mouse, intraperitoneal injection, administered on days 7, 10, and 13 post-inoculation) induced the release of pro-inflammatory cytokines and chemokines in the blood of animals bearing bladder tumors in MB49 mice and affected the composition of tumor bone marrow cells, resulting in a decrease in monocytes and macrophages and an increase in the number of granulocytes. [1]

Human

Monoclonal

Unconjugated